Effects of Yishenjiangzhuo granules on immunity and bone metabolism in patients with stage 3-4 chronic kidney disease

被引:0
|
作者
Jing Zheng [1 ]
Yingda Lin [2 ]
Lu Huang [3 ]
Caifeng Chen [3 ]
Xuemin Zheng [3 ]
Xinhong Wu [3 ]
Ciyun Liu [3 ]
机构
[1] Nephropathy Department, Fujian Provincial People's Hospital
[2] Teaching and Research Section of Internal Medicine, Fujian Provincial People's Hospital
[3] Postgraduate Department, Integration of Traditonal Chinese and Western Medicine, Fujian University of Traditional Chinese Medicine
关键词
B lymphocytes; T-lymphocytes; regulatory; Osteocalcin; Acid phosphatase; Yishenjiangzhuo granules;
D O I
暂无
中图分类号
R692 [肾疾病];
学科分类号
摘要
OBJECTIVE:To determine the effects of Yishenjiangzhuo granules(YJG)on bone metabolism and to explore the changes in levels of bone Gla protein(BGP),tartrate-resistant acid phosphatase(TRAP),as well as their relationships with levels of B cells,regulatory T cells(Treg)and interleukin(IL)-17 in patients with stage 3-4 chronic kidney disease(CKD)before and after treatment.METHODS:Fifty-three stage 3-4 CKD patients were divided randomly into two groups:YJG treatment and control.Peripheral blood was taken from two groups of CKD patients and 21 healthy subjects in the normal group.The parameters determined were the levels of CD4+,CD19+,CD19+CD69+,CD19+AV,Treg(CD4+CD25+CD127lo),BGP,TRAP,IL-17,calcium,phosphate,blood urea nitrogen,serum creatinine(SCr),hemoglobin(Hb)in peripheral blood,and urinary creatinine.Calcium-phosphate products and endogenous creatinine clearance rate(CCr)were calculated according to standard protocols.RESULTS:In YJG and control groups,SCr levels were lowered(P<0.01)after treatment,whereas CCr(P<0.05)as well as Hb and albumin levels(P<0.01)were increased.The changes in levels of CCr and SCr in the YJG group were more significant.After treatment,CD19+CD69+and Treg levels in the two groups varied(P<0.01)compared with those of the normal group;the level of CD19+increased but the levels of CD4+and CD19+AV decreased(P<0.01)in both groups.Compared with the control group,the changes of CD19+and CD19+AV in the YJG group were more apparent(P<0.05).Compared with the normal group,levels of IL-17 in both groups increased significantly(P<0.01),and the difference in the control group was more significant(P<0.05).After treatment,the TRAP level increased(P<0.05),but the difference in BGP level(P>0.05)was not significant.CONCLUSION:In stage 3-4 CKD patients,B cells and IL-17 participated in the induction of osteoclast activation.YJG could also elevate the level of B cells and decrease their apoptosis,but showed no significant effects on active B cells,IL-17 or osteoclast activity.
引用
收藏
页码:620 / 625
页数:6
相关论文
共 50 条
  • [41] Different Effects of Empagliflozin on Markers of Mineral-Bone Metabolism in Diabetic and Non-Diabetic Patients with Stage 3 Chronic Kidney Disease
    Masajtis-Zagajewska, Anna
    Holub, Tomasz
    Peczek, Katarzyna
    Makowka, Agnieszka
    Nowicki, Michal
    MEDICINA-LITHUANIA, 2021, 57 (12):
  • [42] Therapeutic effects of Kangxian Yanshen formula on patients with chronic kidney disease stages 3-4: a retrospective cohort study
    Chu, Aojiao
    Wei, Wenqian
    Liu, Ni
    Zhang, Fan
    Zhang, Xianwen
    Li, Xueling
    Zheng, Rong
    Ma, Zhifang
    Li, Yi
    Rong, Shu
    Zhong, Yifei
    FRONTIERS IN MEDICINE, 2024, 11
  • [43] Markers of bone metabolism in patients with chronic kidney disease (stages 1-4)
    Siamopoulos, Kostas
    Dounousi, Evangelia
    Katopodis, Konstantinos
    Tsouchnikas, Ioannis
    Triantou, Eleni
    Ikonomou, Margarita
    Tsakiris, Dimitrios
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 417 - 418
  • [44] Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
    Chertow, Glenn M.
    Vart, Priya
    Jongs, Niels
    Toto, Robert D.
    Gorriz, Jose Luis
    Hou, Fan Fan
    McMurray, John J. V.
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, C. David
    Stefansson, Bergur V.
    Langkilde, Anna Maria
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (09): : 2352 - 2361
  • [45] Chronic kidney disease and bone metabolism
    Junichiro James Kazama
    Koji Matsuo
    Yoshiko Iwasaki
    Masafumi Fukagawa
    Journal of Bone and Mineral Metabolism, 2015, 33 : 245 - 252
  • [46] Chronic kidney disease and bone metabolism
    Kazama, Junichiro James
    Matsuo, Koji
    Iwasaki, Yoshiko
    Fukagawa, Masafumi
    JOURNAL OF BONE AND MINERAL METABOLISM, 2015, 33 (03) : 245 - 252
  • [47] EFFECTS OF KETOANALOGUES ON THE EVOLUTION OF BONE MINERAL METABOLISM IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE
    Kosmadakis, Georgios
    Rouchon, Myriam Isnard
    Fuentes, Fanny
    Ramade, Nathalie
    Baudenon, Julien
    Deville, Clemence
    Enache, Ioana
    Gueret, Claudine
    Haskour, Abraham
    Necoara, Aura
    Rance, Nicole
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I421 - I421
  • [48] SERUM FETUIN-A AND BONE MINERAL MARKERS AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 3 AND 4
    Krishnasamy, R.
    Elder, G.
    Hawley, C.
    Isbel, N.
    NEPHROLOGY, 2012, 17 : 77 - 77
  • [49] Urate-lowering agents for asymptomatic hyperuricemia in stage 3-4 chronic kidney disease: Controversial role of kidney function
    Jeon, Hee Jung
    Oh, Jieun
    Shin, Dong Ho
    PLOS ONE, 2019, 14 (06):
  • [50] UTILITY OF INTRAVENOUS IRON CARBOXYMALTOSE IN A SINGLE DOSE IN THE CONTROL OF ANEMIA IN CHRONIC KIDNEY DISEASE STAGE 3-4
    Luis Merino, Jose
    Espejo, Beatriz
    Bueno, Blanca
    Amezquita, Yesika
    Paraiso, Vicente
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 363 - 363